Drug reference
Umeclidinium
Antimuscarinic · Bronchodilator
Also known as Umeclidinium bromide
AntimuscarinicBronchodilator
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
Manufacturer advises use only if potential benefit outweighs risk
FDA category + note
Mechanism
Umeclidinium is a long-acting antimuscarinic agent, a synthetic analog of atropine. It acts as a bronchodilator by slowly dissociating from M3 receptors on bronchial smooth muscle cells. This action helps to reduce bronchoconstriction and allows for once-daily administration due to its prolonged effect.
Indications
Maintenance treatment of chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease (COPD)
Dosing
- Adult
- 55 micrograms once daily by inhalation of powder
- Hepatic adjustment
- Manufacturer advises caution in severe impairment
Pharmacokinetics
Duration
Longer bronchodilator action, enabling once-daily administration
Half-life
11 hours
Side effects
Common
Taste altered
Serious
- Eye pain
Pregnancy & lactation
Pregnancy
Manufacturer advises use only if potential benefit outweighs risk
Lactation
Manufacturer advises avoid—no information available
Related guidelines
Other Antimuscarinic drugs
Ask House about Umeclidinium
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team